Hemophilia Drugs

Global Market Trajectory & Analytics

MCP12344

EXECUTIVE ENGAGEMENTS

POOL

3121
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

562
Interactions with Platform & by Email

PARTICIPANTS

94
Unique # Participated

VALIDATIONS

27
Responses Validated*

COMPANIES

15
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

108

PAGES

153

EDITION

7

PRICE

USD 4950

CODE

MCP12344


COMPETITIVE METRICS

COMPANY

D S N T

% *

Alnylam Pharmaceuticals, Inc.

Amarna Therapeutics

Asklepios Biopharmaceutical, Inc.

Bayer AG

Biogen, Inc.

BioMarin Pharmaceutical, Inc.

Catalyst Biosciences, Inc.

Chiesi Farmaceutici SpA

CSL Behring

Dimension Therapeutics, Inc.

View More...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Hemophilia Drugs estimated at US$12.1 Billion in the year 2020, is projected to reach a revised size of US$16.7 Billion by 2027, growing at a CAGR of 4.7% over the analysis period 2020-2027. Hemophilia A Drugs, one of the segments analyzed in the report, is projected to record a 4.5% CAGR and reach US$12.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hemophilia Inhibitors Treatment segment is readjusted to a revised 5.6% CAGR for the next 7-year period.
The Hemophilia Drugs market in the U.S. is estimated at US$3.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$3 Billion by the year 2027 trailing a CAGR of 4.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.3% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.
In the global Hemophilia B Drugs segment, USA, Canada, Japan, China and Europe will drive the 5.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.4 Billion in the year 2020 will reach a projected size of US$2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.9 Billion by the year 2027.

SELECT PLAYERS

Alnylam Pharmaceuticals, Inc.; Amarna Therapeutics; Asklepios Biopharmaceutical, Inc.; Bayer AG; Biogen, Inc.; BioMarin Pharmaceutical, Inc.; Catalyst Biosciences, Inc.; Chiesi Farmaceutici SpA; CSL Behring LLC; Dimension Therapeutics, Inc.; Emergent BioSolutions, Inc.; F. Hoffmann-La Roche AG; Grifols SA; Kedrion Biopharma, Inc.; Novo Nordisk A/S; Octapharma AG; Opko Biologics; Pfizer, Inc.; rEVO Biologics, Inc.; Sangamo Therapeutics; Spark Therapeutics, Inc.; Swedish Orphan Biovitrum AB; UniQure N.V.

SEGMENTS

» Type (Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs, Von Willebrand Disease Treatment) » Type of Disease Management (Prophylaxis, On-Demand Therapy, Inhibitor Therapy)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Hemophilia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Hemophilia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hemophilia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Hemophilia A Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Hemophilia A Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hemophilia A Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Hemophilia Inhibitors Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Hemophilia Inhibitors Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hemophilia Inhibitors Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Hemophilia B Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Hemophilia B Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hemophilia B Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Von Willebrand Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Von Willebrand Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Von Willebrand Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Prophylaxis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for On-Demand Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for On-Demand Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for On-Demand Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Inhibitor Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Inhibitor Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Inhibitor Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Hemophilia Drugs by Type Of Disease Management - Percentage Breakdown of Value Sales for Prophylaxis, On-Demand Therapy and Inhibitor Therapy for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Hemophilia Drugs by Type Of Disease Management - Percentage Breakdown of Value Sales for Prophylaxis, On-Demand Therapy and Inhibitor Therapy for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Hemophilia Drugs by Type Of Disease Management - Percentage Breakdown of Value Sales for Prophylaxis, On-Demand Therapy and Inhibitor Therapy for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment for the Years 2012, 2020 & 2027
China Current & Future Analysis for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Hemophilia Drugs by Type Of Disease Management - Percentage Breakdown of Value Sales for Prophylaxis, On-Demand Therapy and Inhibitor Therapy for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Hemophilia Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for Hemophilia Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Hemophilia Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Hemophilia Drugs by Type Of Disease Management - Percentage Breakdown of Value Sales for Prophylaxis, On-Demand Therapy and Inhibitor Therapy for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment for the Years 2012, 2020 & 2027
France Current & Future Analysis for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Hemophilia Drugs by Type Of Disease Management - Percentage Breakdown of Value Sales for Prophylaxis, On-Demand Therapy and Inhibitor Therapy for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Hemophilia Drugs by Type Of Disease Management - Percentage Breakdown of Value Sales for Prophylaxis, On-Demand Therapy and Inhibitor Therapy for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Hemophilia Drugs by Type Of Disease Management - Percentage Breakdown of Value Sales for Prophylaxis, On-Demand Therapy and Inhibitor Therapy for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Hemophilia Drugs by Type Of Disease Management - Percentage Breakdown of Value Sales for Prophylaxis, On-Demand Therapy and Inhibitor Therapy for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Hemophilia Drugs by Type Of Disease Management - Percentage Breakdown of Value Sales for Prophylaxis, On-Demand Therapy and Inhibitor Therapy for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Hemophilia Drugs by Type Of Disease Management - Percentage Breakdown of Value Sales for Prophylaxis, On-Demand Therapy and Inhibitor Therapy for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Hemophilia Drugs by Type - Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Hemophilia Drugs by Type - Percentage Breakdown of Value Sales for Hemophilia A Drugs, Hemophilia Inhibitors Treatment, Hemophilia B Drugs and Von Willebrand Disease Treatment for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Hemophilia Drugs by Type Of Disease Management - Prophylaxis, On-Demand Therapy and Inhibitor Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Hemophilia Drugs by Type Of Disease Management - Percentage Breakdown of Value Sales for Prophylaxis, On-Demand Therapy and Inhibitor Therapy for the Years 2012, 2020 & 2027
Total Companies Profiled: 15

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com